Hans Furuland

Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Svensson, Maria K.; Nassar, Rita; Melin, Jan; Lindberg, Magnus et al.

Ingår i BMC Nephrology, 2025

• DOI för Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis
• Ladda ner fulltext (pdf) av Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Furuland, Hans; Larsson, Anders Olof; Bjellerup, Per; Uhde, Milica et al.

Ingår i BMC Nephrology, s. 213, 2025

• DOI för Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.
• Ladda ner fulltext (pdf) av Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

Dasgupta, Indranil; Bagnis, Corinne Isnard; Floris, Matteo; Furuland, Hans et al.

Ingår i Clinical Kidney Journal, 2024

• DOI för Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance
• Ladda ner fulltext (pdf) av Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis

Erkapers, Maria; Frykholm, Carina; Furuland, Hans; Segerstrom, Susanna et al.

Ingår i Upsala Journal of Medical Sciences, 2024

• DOI för A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis
• Ladda ner fulltext (pdf) av A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

Bredewold, Obbo W; Chan, Joe; Svensson, My; Bruchfeld, Annette et al.

Ingår i Kidney Medicine, 2023

• DOI för Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
• Ladda ner fulltext (pdf) av Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Svensson, Maria K.; Nassar, Rita; Melin, Jan; Lindberg, Magnus et al.

Ingår i BMC Nephrology, 2025

• DOI för Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis
• Ladda ner fulltext (pdf) av Brain natriuretic peptide and all-cause mortality in patients treated with haemodialysis

Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Furuland, Hans; Larsson, Anders Olof; Bjellerup, Per; Uhde, Milica et al.

Ingår i BMC Nephrology, s. 213, 2025

• DOI för Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.
• Ladda ner fulltext (pdf) av Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare-the DEMONSTRATE database.

Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

Dasgupta, Indranil; Bagnis, Corinne Isnard; Floris, Matteo; Furuland, Hans et al.

Ingår i Clinical Kidney Journal, 2024

• DOI för Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance
• Ladda ner fulltext (pdf) av Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance

A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis

Erkapers, Maria; Frykholm, Carina; Furuland, Hans; Segerstrom, Susanna et al.

Ingår i Upsala Journal of Medical Sciences, 2024

• DOI för A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis
• Ladda ner fulltext (pdf) av A case of enamel renal syndrome from a novel genetic mutation, multidisciplinary management and long-term prognosis

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

Bredewold, Obbo W; Chan, Joe; Svensson, My; Bruchfeld, Annette et al.

Ingår i Kidney Medicine, 2023

• DOI för Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
• Ladda ner fulltext (pdf) av Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial

Eklund, Michael; Hellberg, Olof; Furuland, Hans; Cao, Yang et al.

Ingår i Upsala Journal of Medical Sciences, 2022

• DOI för Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial
• Ladda ner fulltext (pdf) av Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial

Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden

Kim, Kun; Fagerström, Josefine; Chen, Gengshi; Lagunova, Zoya et al.

Ingår i BMC Nephrology, 2022

• DOI för Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden
• Ladda ner fulltext (pdf) av Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden

Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial

Eklund, Michael; Hellberg, Olof; Furuland, Hans; Cao, Yang et al.

Ingår i Upsala Journal of Medical Sciences, 2021

• DOI för Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial
• Ladda ner fulltext (pdf) av Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Wheeler, David C.; Stefansson, Bergur; Batiushin, Mikhail; Bilchenko, Oleksandr et al.

Ingår i Nephrology, Dialysis and Transplantation, s. 1700-1711, 2020

• DOI för The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Systematic fluid assessment in haemodialysis: Development and validation of a decision aid

Stenberg, Jenny; Keane, David; Lindberg, Magnus; Furuland, Hans

Ingår i Journal of Renal Care, s. 52-61, 2020

• DOI för Systematic fluid assessment in haemodialysis: Development and validation of a decision aid
• Ladda ner fulltext (pdf) av Systematic fluid assessment in haemodialysis: Development and validation of a decision aid

Implementation of a decision aid for recognition and correction of volume alterations (Recova^®) in haemodialysis patients

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

Ingår i Upsala Journal of Medical Sciences, s. 281-292, 2020

• DOI för Implementation of a decision aid for recognition and correction of volume alterations (Recova^®) in haemodialysis patients
• Ladda ner fulltext (pdf) av Implementation of a decision aid for recognition and correction of volume alterations (Recova^®) in haemodialysis patients

Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)

Jensen, Gert; Göransson, Lasse G.; Femström, Anders; Furuland, Hans et al.

Ingår i Clinical Nephrology, s. 246-253, 2019

• DOI för Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

Evans, Marc; Palaka, Eirini; Furuland, Hans; Bennett, Hayley et al.

Ingår i BMC Nephrology, 2019

• DOI för The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease
• Ladda ner fulltext (pdf) av The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease

Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients

Stenberg, Jenny; Melin, Jan; Lindberg, Magnus; Furuland, Hans

Ingår i Hemodialysis International, s. 402-413, 2019

• DOI för Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients
• Ladda ner fulltext (pdf) av Brain natriuretic peptide reflects individual variation in hydration status in hemodialysis patients

Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK

Linde, Cecilia; Qin, Lei; Bakhai, Ameet; Furuland, Hans et al.

Ingår i ESC Heart Failure, s. 280-290, 2019

• DOI för Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK
• Ladda ner fulltext (pdf) av Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK

Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

Linde, Cecilia; Bakhai, Ameet; Furuland, Hans; Evans, Marc et al.

Ingår i Journal of the American Heart Association, 2019

• DOI för Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom
• Ladda ner fulltext (pdf) av Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

Perspectives on clinical use of bioimpedance in hemodialysis: focus group interviews with renal care professionals

Stenberg, Jenny; Henriksson, Catrin; Lindberg, Magnus; Furuland, Hans

Ingår i BMC Nephrology, 2018

• DOI för Perspectives on clinical use of bioimpedance in hemodialysis: focus group interviews with renal care professionals
• Ladda ner fulltext (pdf) av Perspectives on clinical use of bioimpedance in hemodialysis: focus group interviews with renal care professionals

RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD

Furuland, Hans; McEwan, Phil; Evans, Marc; Linde, Cecilia et al.

Ingår i Nephrology, Dialysis and Transplantation, s. 157-157, 2018

• DOI för RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD

RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD

Linde, Cecilia; McEwan, Phil; Bakhai, Ameet; Furuland, Hans et al.

Ingår i Nephrology, Dialysis and Transplantation, s. 145-145, 2018

• DOI för RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD

Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Furuland, Hans; McEwan, Phil; Evans, Marc; Linde, Cecilia et al.

Ingår i BMC Nephrology, 2018

• DOI för Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink
• Ladda ner fulltext (pdf) av Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.

Bakhai, Ameet; Palaka, Eirini; Linde, Cecilia; Bennett, Hayley et al.

Ingår i Journal of Medical Economics, s. 1172-1182, 2018

• DOI för Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure.

Clinical praxis for assessment of dry weight in Sweden and Denmark: A mixed-methods study

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

Ingår i Hemodialysis International, s. 111-119, 2016

• DOI för Clinical praxis for assessment of dry weight in Sweden and Denmark: A mixed-methods study
• Ladda ner fulltext (pdf) av Clinical praxis for assessment of dry weight in Sweden and Denmark: A mixed-methods study

Heart rate variability is decreased in chronic kidney disease but may improve with hemoglobin normalization

Furuland, Hans; Linde, Torbjörn; Englund, Anders; Wikström, Björn

Ingår i JN. Journal of Nephrology (Milano. 1992), s. 45-52, 2008

Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha

Furuland, Hans; Linde, Torbjörn; Sandhagen, Bo; Andrén, Bertil et al.

Ingår i Scandinavian Journal of Urology and Nephrology, s. 399-404, 2005

• DOI för Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin-alpha

Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: Results from a Swedish multicentre survey

Linde, Torbjörn; Furuland, Hans; Wikström, Björn

Ingår i Scandinavian Journal of Urology and Nephrology, s. 329-333, 2005

• DOI för Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: Results from a Swedish multicentre survey

Reduced hemodialysis adequacy after hemoglobin normalization with epoetin

Furuland, Hans; Linde, Torbjörn; Wikström, Björn; Danielson, Bo G.

Ingår i JN. Journal of Nephrology (Milano. 1992), s. 80-85, 2005

A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients

Furuland, Hans; Linde, Torbjörn; Ahlmén, Jarl; Christensson, Anders et al.

Ingår i Nephrology, Dialysis and Transplantation, s. 353-361, 2003

• DOI för A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients

Implementation of a Decision Aid for Recognition and Correction ofVolume Alterations (Recova®) in Hemodialysis

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

s. 24-24, 2020

Systematic fluid assessment in haemodialysis care: Development and validation of adecision aid

Stenberg, Jenny; Keane, David; Lindberg, Magnus; Furuland, Hans

s. 85-85, 2019

Bedside BNP as a marker of overhydration in hemodialysis patients

Melin, Jan; Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

s. 878-878, 2017

Clinical praxis for assessment of dry weight in Sweden and Denmark: a mixed-methods study

Stenberg, Jenny; Lindberg, Magnus; Furuland, Hans

s. 108-108, 2015